Liver cancer cells: Targeting and prolonged-release drug carriers consisting of mesoporous silica nanoparticles and alginate microspheres
Journal
International Journal of Nanomedicine
Journal Volume
9
Journal Issue
1
Pages
2767-2778
Date Issued
2014
Author(s)
Abstract
A new microsphere consisting of inorganic mesoporous silica nanoparticles (MSNs) and organic alginate (denoted as MSN@Alg) was successfully synthesized by air-dynamic atomization and applied to the intracellular drug delivery systems (DDS) of liver cancer cells with sustained release and specific targeting properties. MSN@Alg microspheres have the advantages of MSN and alginate, where MSN provides a large surface area for high drug loading and alginate provides excellent biocompatibility and COOH functionality for specific targeting. Rhodamine 6G was used as a model drug, and the sustained release behavior of the rhodamine 6G-loaded MSN@Alg microspheres can be prolonged up to 20 days. For targeting therapy, the anticancer drug doxorubicin was loaded into MSN@Alg microspheres, and the (lysine)4-tyrosine-arginine-glycine-aspartic acid (K4YRGD) peptide was functionalized onto the surface of MSN@Alg for targeting liver cancer cells, hepatocellular carcinoma (HepG2). The results of the 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) assay and confocal laser scanning microscopy indicate that the MSN@Alg microspheres were successfully uptaken by HepG2 without apparent cytotoxicity. In addition, the intracellular drug delivery efficiency was greatly enhanced (ie, 3.5-fold) for the arginine-glycine-aspartic acid (RGD)-labeled, doxorubicin-loaded MSN@Alg drug delivery system compared with the non-RGD case. The synthesized MSN@Alg microspheres show great potential as drug vehicles with high biocompatibility, sustained release, and targeting features for future intracellular DDS. ? 2014 Liao et al.
Subjects
Alginate; Atomization; Mesoporous silica nanoparticles; Sustained release; Targeting therapy
SDGs
Other Subjects
alginic acid; arginylglycylaspartic acid; doxorubicin; drug carrier; microsphere; nanoparticle; rhodamine 6G; silicon dioxide; alginic acid; alginic acid; arginyl-glycyl-aspartic acid; delayed release formulation; doxorubicin; glucuronic acid; hexuronic acid; nanocapsule; oligopeptide; silicon dioxide; article; biocompatibility; controlled study; drug targeting; drug uptake; endocytosis; HepG2 cell line; human; human cell; molecularly targeted therapy; surface property; sustained drug release; administration and dosage; animal; chemistry; delayed release formulation; diffusion; HepG2 cell line; Liver Neoplasms, Experimental; metabolism; pathology; porosity; procedures; treatment outcome; Alginates; Animals; Delayed-Action Preparations; Diffusion; Doxorubicin; Glucuronic Acid; Hep G2 Cells; Hexuronic Acids; Humans; Liver Neoplasms, Experimental; Molecular Targeted Therapy; Nanocapsules; Oligopeptides; Porosity; Silicon Dioxide; Treatment Outcome
Type
journal article